Chester County News and Community Website
PHILADELPHIA, PA — Latus Bio, Inc. has announced a significant advancement in the field of gene therapy with the publication of its latest research in Nature Communications. The study, led …
Latus Bio Unveils Breakthrough in Gene Therapy for Neurodegenerative Diseases Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biopharmaceutical company, is set to showcase significant advancements in its treatments for Alzheimer’s disease (AD) and Parkinson’s disease (PD) at the …
Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 Read More
WEST CHESTER, PA — Pathways Neuro Pharma Inc. has announced a significant pivot in its development pipeline, prioritizing rare pediatric neurological disorders, with Juvenile Parkinson’s Disease (JPD) leading the charge. This …
Pathways Neuro Pharma Targets Rare Pediatric Neurological Disorders with Pioneering Gene Therapy Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) will hold a live webcast aimed at providing patients, caregivers, and families with updates on its clinical trials and future plans. The virtual …
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has made strides in the fight against neurodegenerative diseases with the filing of three new patents. These cover novel combination therapies involving their …
Annovis Bio Files Patents for Innovative Therapies in Neurodegenerative Disease Treatment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has received approval from the U.S. Food and Drug Administration (FDA) to transition to a new solid form of buntanetap in future …
Annovis Bio Gains FDA Approval for New Form of Neurodegenerative Drug Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) recently disclosed the encouraging results of its Phase III clinical trial related to Parkinson’s disease treatment. The experimental drug, buntanetap, has shown …
Annovis Bio’s Breakthrough in Parkinson’s Treatment: New Drug Buntanetap Shows Promise Read More
DOYLESTOWN, PA — Kannalife Sciences, Inc. has received a $1.49 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This funding will support preclinical research on Kannalife’s …
Kannalife Sciences Secures $1.49 Million Grant for Parkinson’s Research Read More
WEST BRANDYWINE, PA — In an inspiring show of community spirit and commitment, Freedom Village at Brandywine marked World Parkinson’s Day by joining the “Pump it for Parkinson’s” initiative led …
Freedom Village Steps Up for Parkinson’s Awareness with Record-Breaking Initiative Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) has recently announced the completion of the last patient visit in its phase III study of buntanetap, a leading candidate for treating …
Annovis Bio Finalizes Phase III Study of Buntanetap in Early Parkinson’s Treatment, Awaits Topline Data Read More